Rationale, Strengths, and Limitations of Real-World Evidence in Oncology: A Canadian Review and Perspective
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Randomized controlled trials (RCTs) continue to be the basis for essential evidence regarding the efficacy of interventions such as cancer therapies. Limitations associated with RCT designs, including selective study populations, strict treatment regimens, and being time-limited, mean they do not provide complete information about an intervention’s safety or the applicability of the trial’s results to a wider range of patients seen in real-world clinical practice. For example, recent data from Alberta showed that almost 40% of patients in the province’s cancer registry would be trial-ineligible per common exclusion criteria. Real-world evidence (RWE) offers an opportunity to complement the RCT evidence base with this kind of information about safety and about use in wider patient populations. It is also increasingly recognized for being able to provide information about an intervention’s effectiveness and is considered by regulators as an important component of the evidence base in drug approvals. Here, we examine the limitations of RCTs in oncology research, review the different types of RWE available in this area, and discuss the strengths and limitations of RWE for complementing RCT oncology data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These observational studies are at moderate to high risk of bias and have several limitations that hinder causal inference, including lack of randomization and reliance on medical claims and medical record documentation for the evaluation of exposure (e.g.,. GLP-1 RA use) and outcomes (e.g., thyroid cancer and subtypes).50”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Observational studies using data generated as part of clinical practice can provide real-world evidence of effectiveness and safety. Yet, they are prone to confounding and biases that hinder causal inference, in this case, supporting a causal association between GLP-1 RA use and development or diagnosis of thyroid cancer.49,50”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
Constructing Inverse Probability Weights for Marginal Structural Models
Cole, S. R., & Hernan, M. A. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn164 · Cited by 2,796
Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities
Murthy, V. H., Krumholz, H. M., & Gross, C. P. (2004) · JAMA · doi:10.1001/jama.291.22.2720 · Cited by 2,078
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Kennedy-Martin, T., Curtis, S., Faries, D., Robinson, S., & Johnston, J. (2015) · Trials · doi:10.1186/s13063-015-1023-4 · Cited by 878
Lund, J. L., Richardson, D. B., & Stürmer, T. (2015) · Current Epidemiology Reports · doi:10.1007/s40471-015-0053-5 · Cited by 739
Desai, R. J., & Franklin, J. M. (2019) · BMJ · doi:10.1136/bmj.l5657 · Cited by 657
Amir, E., Seruga, B., Niraula, S., Carlsson, L., & Ocaña, A. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr242 · Cited by 622
Propensity Score Methods for Confounding Control in Nonexperimental Research
Brookhart, M. A., Wyss, R., Layton, J. B., & Stürmer, T. (2013) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000359 · Cited by 588
Godwin, M., Ruhland, L., Casson, I., MacDonald, S., Delva, D., Birtwhistle, R., Lam, M., & Seguin, R. (2003) · BMC Medical Research Methodology · doi:10.1186/1471-2288-3-28 · Cited by 506
Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations
Korde, L. A., Zujewski, J. A., Kamin, L., Giordano, S., Domchek, S., Anderson, W. F., Bartlett, J. M. S., Gelmon, K., Nahleh, Z., Bergh, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.5729 · Cited by 487
Developing a Protocol for Observational Comparative Effectiveness Research: A User's Guide
Velentgas, P., Dreyer, N. A., Nourjah, P. A., Smith, S. R., & Torchia, M. (2013) · Cited by 380
Real-world Data for Clinical Evidence Generation in Oncology
Khozin, S., Blumenthal, G. M., & Pazdur, R. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx187 · Cited by 346 · cited 3×
“4 The official Health Canada notification lists 3 scenarios for which RWE submissions are encouraged: (1) to expand evidence-based indications for populations frequently excluded from clinical studies; (2) for drugs or diseases where clinical studies are unfeasible (eg, rare diseases); and (3) for drugs or diseases wh…”
BackgroundMethodEvaluating eligibility criteria of oncology trials using real-world data and AI
Liu, R., Rizzo, S., Whipple, S., Pal, N., Pineda, A. L., Lu, M., Arnieri, B., Lu, Y., Capra, W., Copping, R., et al. (2021) · Nature · doi:10.1038/s41586-021-03430-5 · Cited by 322
Trial designs using real‐world data: The changing landscape of the regulatory approval process
Baumfeld Andre, E., Reynolds, R., Caubel, P., Azoulay, L., & Dreyer, N. A. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4932 · Cited by 252
Self-citationNaci, H., Davis, C., Savović, J., Higgins, J. P. T., Sterne, J. A. C., Gyawali, B., Romo-Sandoval, X., Handley, N., & Booth, C. M. (2019) · BMJ · doi:10.1136/bmj.l5221 · Cited by 243
Suissa, S., Moodie, E. E. M., & Dell'Aniello, S. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4107 · Cited by 239
Khosrow-Khavar, F., Filion, K. B., Al-Qurashi, S., Torabi, N., Bouganim, N., Suissa, S., & Azoulay, L. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw673 · Cited by 208
Self-citationEnhancing global access to cancer medicines
Cortes, J., Perez‐García, J. M., Llombart‐Cussac, A., Curigliano, G., El Saghir, N. S., Cardoso, F., Barrios, C. H., Wagle, S., Roman, J., Harbeck, N., et al. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21597 · Cited by 203
Harbeck, N., Iyer, S., Turner, N., Cristofanilli, M., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Bhattacharyya, H., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw139 · Cited by 176
Time‐related biases in pharmacoepidemiology
Suissa, S., & Dell'Aniello, S. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5083 · Cited by 173
Real-World Evidence in Oncology: Opportunities and Limitations
Di Maio, M., Perrone, F., & Conte, P. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0647 · Cited by 168
Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer
Khosrow‐Khavar, F., Filion, K. B., Bouganim, N., Suissa, S., & Azoulay, L. (2020) · Circulation · doi:10.1161/circulationaha.119.044750 · Cited by 156
Self-citationRugo, H. S., Diéras, V., Gelmon, K. A., Finn, R. S., Slamon, D. J., Martin, M., Neven, P., Shparyk, Y., Mori, A., Lu, D. R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy012 · Cited by 153
Yalaza, M., İnan, A., & Bozer, M. (2016) · Meme sağlığı dergisi/Meme sağlığı dergisi · doi:10.5152/tjbh.2015.2711 · Cited by 144
Relevance of randomised controlled trials in oncology
Tannock, I. F., Amir, E., Booth, C. M., Niraula, S., Ocaña, A., Šeruga, B., Templeton, A. J., & Vera-Badillo, F. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30572-1 · Cited by 131
Bogaerts, J., Sydes, M. R., Keat, N., McConnell, A., Benson, A., Ho, A., Roth, A., Fortpied, C., Eng, C., Peckitt, C., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2014.10.027 · Cited by 129
Gökbuget, N., Kelsh, M., Chia, V, Advani, A., Bassan, R., Dombret, H., Doubek, M., Fielding, A. K., Giebel, S., Haddad, V, et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.84 · Cited by 125
Cuppone, F., Bria, E., Verma, S., Pritchard, K. I., Gandhi, S., Carlini, P., Milella, M., Nisticò, C., Terzoli, E., Cognetti, F., et al. (2007) · Cancer · doi:10.1002/cncr.23171 · Cited by 122
Malorni, L., Curigliano, G., Minisini, A. M., Cinieri, S., Tondini, C. A., D’Hollander, K., Arpino, G., Bernardo, A., Martignetti, A., Criscitiello, C., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy214 · Cited by 110
Cardiovascular Disease After Aromatase Inhibitor Use
Haque, R., Shi, J. M., Schottinger, J. E., Chung, J., Avila, C. C., Amundsen, B. I., Xu, X., Barac, A., & Chlebowski, R. T. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0429 · Cited by 106
Challenging Standard-of-Care Paradigms in the Precision Oncology Era
Subbiah, V., & Kurzrock, R. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2017.12.004 · Cited by 89
Use of Real-world Data for New Drug Applications and Line Extensions
Bolislis, W. R., Fay, M., & Kühler, T. C. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.03.006 · Cited by 85
Abdel-Qadir, H. M., Amir, E., Fischer, H. D., Fu, L., Austin, P. C., Harvey, P., Rochon, P. A., Lee, D. S., & Anderson, G. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.08.022 · Cited by 82
Eichler, H., König, F., Arlett, P. R., Enzmann, H. G., Humphreys, A., Pétavy, F., Schwarzer‐Daum, B., Sepodes, B. M. N., Vamvakas, S., & Rasi, G. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1638 · Cited by 75
Can real-world data really replace randomised clinical trials?
Ramagopalan, S. V., Simpson, A., & Sammon, C. (2020) · BMC Medicine · doi:10.1186/s12916-019-1481-8 · Cited by 74
Generalisability of Common Oncology Clinical Trial Eligibility Criteria in the Real World
Karim, S., Xu, Y., Kong, S., Abdel-Rahman, O., Quan, M. L., & Cheung, W. Y. (2019) · Clinical Oncology · doi:10.1016/j.clon.2019.05.003 · Cited by 64
Chan, K., Nam, S., Evans, B., de Oliveira, C., Chambers, A., Gavura, S., Hoch, J. S., Mercer, R. E., Dai, W. F., Beca, J. M., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-032884 · Cited by 52
Ligibel, J. A., O’Malley, A. J., Fisher, M. D., Daniel, G. W., Winer, E. P., & Keating, N. L. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1754-1 · Cited by 51
Kraus, A. L., Yu‐Kite, M., Mardekian, J., Cotter, M. J., Kim, S., Decembrino, J., Snow, T., Carson, K. R., Rockland, J. M., Gossai, A., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2454 · Cited by 47
Real-World Evidence and Randomized Studies in the Precision Oncology Era: The Right Balance
Gyawali, B., Parsad, S., Feinberg, B. A., & Nabhan, C. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00132 · Cited by 45
Luke, J. J., Ghate, S. R., Kish, J. K., Lee, C. H., McAllister, L., Mehta, S., Ndife, B. C., & Feinberg, B. A. (2019) · Future Oncology · doi:10.2217/fon-2018-0964 · Cited by 40
Kamaraju, S., Shi, Y., Smith, E. C., Nattinger, A. B., Laud, P. W., & Neuner, J. M. (2018) · Clinical Cardiology · doi:10.1002/clc.23114 · Cited by 34
Role of Real-World Evidence in Informing Cancer Care: Lessons from Colorectal Cancer
Batra, A., & Cheung, W. Y. (2019) · Current Oncology · doi:10.3747/co.26.5625 · Cited by 31
Abrahami, D., Pradhan, R., Yin, H., Honig, P. K., Andre, E. B., & Azoulay, L. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2012 · Cited by 27
Self-citationO’Donnell, J. C., Le, T. K., Dobrin, R., Higashi, M. K., Pereira, A., Wagner, S., Yang, A. S., & Hukkelhoven, M. (2020) · Future Oncology · doi:10.2217/fon-2020-0591 · Cited by 21
Cardiotoxicity of Use of Sequential Aromatase Inhibitors in Women With Breast Cancer
Khosrow‐Khavar, F., Bouganim, N., Filion, K. B., Suissa, S., & Azoulay, L. (2020) · American Journal of Epidemiology · doi:10.1093/aje/kwaa065 · Cited by 19
Self-citationVisualization of Sequential Treatments in Metastatic Breast Cancer
Rocque, G. B., Kandhare, P., Williams, C., Nakhmani, A., Azuero, A., Burkard, M. E., Forero, A., Bhatia, S., & Kenzik, K. M. (2019) · JCO Clinical Cancer Informatics · doi:10.1200/cci.18.00095 · Cited by 14
Treatment Sequencing in Oncology: Balancing Clinical Trial and Real-World Evidence
Caffo, O. (2019) · Future Oncology · doi:10.2217/fon-2019-0415 · Cited by 13
Kostos, L. K., Hong, W., Lee, B., Tran, B., Lok, S. W., Anton, A., Gard, G., To, Y. H., Wong, V., Shapiro, J. D., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33568 · Cited by 12
Research works printed but not linked: 1
- Setoguchi, 2013, Chapter 5: comparator selection.
Cited by
ESMO guidance for reporting oncology real-world evidence (GROW)
Castelo-Branco, L., Pellat, A., Martins-Branco, D., Valachis, A., Derksen, J. W. G., Suijkerbuijk, K. P. M., Dafni, U., Dellaporta, T., Vogel, A., Prelaj, A., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.001 · Cited by 247
ESMO Guidance for Reporting Oncology real-World evidence (GROW)
Castelo-Branco, L., Pellat, A., Martins-Branco, D. A., Valachis, A., Derksen, J. W. G., Suijkerbuijk, K. P. M., Dafni, U. G., Dellaporta, T., Vogel, A., Prelaj, A., et al. (2023) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2023.10.001 · Cited by 40
Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review
Espinosa De Ycaza, A. E., Brito, J. P., McCoy, R. G., Shao, H., & Singh Ospina, N. (2024) · Thyroid · doi:10.1089/thy.2023.0530 · Cited by 37
“49,50 T h e l ea v e on e - ou t a n a l y s i s s ho w e d t h a t t h e e x c l u s i on o f non e o f t h e i n c l ud e d s t ud i e s m od i fi e d t h e e x t e n t o f t h e e ff ec t , bu t l ea v e ou t o f fi v e s t ud i e s w e r e i d e n ti fi e d w ho s e e x c l u s i on w ou l d l ea…”
stefanolo, J. P., Segura, V., Grizzuti, M., Heredia, A., Comino, I., Costa, A. F., Puebla, R. A., Temprano, M. P., Niveloni, S. I., de Diego, G. A., et al. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i11.1545 · Cited by 32
“Consequently, the enforced stay-at-home measures during this time may have contributed to improved adherence to the GFD, as has been suggested by a recent study[31].”
Gandaglia, G., Pellegrino, F., Golozar, A., Meulder, B. D., Abbott, T., Achtman, A. H., Omar, M. I., Alshammari, T. M., Areia, C. M., Asiimwe, A., et al. (2023) · European Urology · doi:10.1016/j.eururo.2023.06.012 · Cited by 20
“Therefore, these might be less generalizable at a population level, where 40% of cancer patients would be eligible in RCTs [9].”
Background
Metadata
- Authors
- Azoulay, L.
- Affiliations
- Jewish General Hospital (CA)
- Corresponding author
- Azoulay, Laurent
- ORCID
- Azoulay, Laurent
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-06-28
- Volume
- 27
- Issue
- 9
- Pages
- e731-e738
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- PMC
- PMC9438907
- OpenAlex
- W4283693701
- Semantic Scholar
- be428d13a690826d0c488243ced0486f25cb7e18
- Cited by
- 79
- References
- 52
- Citations by year
- 2026: 24 · 2025: 28 · 2024: 15 · 2023: 11 · 2022: 1
- FWCI
- 10.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The Oncologist (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Pfizer Canada
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Physical Sciences › Mathematics › Statistics and Probability › Advanced Causal Inference Techniques
- Keywords
- real-world evidence, oncology, randomized controlled trials, inclusion and exclusion criteria, cancer registry, drug approval, drug safety, effectiveness
- MeSH terms
- Canada, Humans, Medical Oncology, Neoplasms, Registries, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.